Loading…
ORIC Pharmaceuticals, Inc. is projected to rise to $12.32 by 2027, a +14% move from its current price of $10.85. ORIC is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $10.48 | $10.85 | $11.24 | +0.03% |
| Jul 14 | $10.33 | $10.86 | $11.41 | +0.07% |
| Jul 15 | $10.22 | $10.86 | $11.54 | +0.10% |
| Jul 16 | $10.13 | $10.86 | $11.65 | +0.13% |
| Jul 17 | $10.05 | $10.87 | $11.75 | +0.16% |
| Jul 18 | $9.98 | $10.87 | $11.84 | +0.20% |
| Jul 19 | $9.91 | $10.87 | $11.93 | +0.23% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $9.91 | $10.87 | $11.93 | +0.23% |
| Week 2 | $9.56 | $10.90 | $12.42 | +0.46% |
| Week 3 | $9.31 | $10.93 | $12.82 | +0.69% |
| Week 4 | $9.10 | $10.95 | $13.18 | +0.92% |
| Week 5 | $8.93 | $10.98 | $13.50 | +1.16% |
| Week 6 | $8.77 | $11.00 | $13.80 | +1.39% |
| Week 7 | $8.63 | $11.03 | $14.08 | +1.62% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on countering resistance mechanisms in cancers in the United States. Its clinical-stage product candidates include enozertinib (ORIC-114), a brain penetrant orally bioavailable irreversible inhibitor that selectively targets EGFR exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency toward exon 20 insertion mutations; and rinzimetostat (ORIC-944), an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently in Phase 1b study.
The company has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC-944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
ORIC Pharmaceuticals, Inc. (ORIC) trades at $10.89 per share. Its market cap is $1.13B and it ranks 2492. The stock is positioned within the healthcare sector and operates as a clinical-stage biopharmaceutical company.
A major floor 46.0% below — a decisive break under it would weaken the trend.
The nearest floor, 30.9% below — buyers have tended to step in here.
The nearest ceiling, 7.3% above — a clean break opens room to run.
A major ceiling 30.3% above — clearing it would confirm fresh momentum.
Key ORIC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ORIC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $10.90 | Sell | $10.87 | Sell |
| MA 10 | $10.75 | Buy | $10.59 | Buy |
| MA 20 | $9.71 | Buy | $10.01 | Buy |
| MA 50 | $9.01 | Buy | $9.57 | Buy |
| MA 100 | $10.18 | Buy | $9.80 | Buy |
| MA 200 | $10.67 | Buy | $10.02 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 64.98 | Neutral |
| Stoch RSI (14) | 41.81 | Neutral |
| CCI (20) | 71.67 | Neutral |
| Williams %R (14) | -28.94 | Info |
| MACD (12,26,9) | 0.14 | Buy |
| ROC (12) | 21.77 | Buy |
| Bollinger %B (20,2) | 0.75 | Neutral |
| Stochastic %K (14) | 71.06 | Neutral |
| TRIX (15) | 0.88 | Buy |
| Awesome (5,34) | 1.84 | Buy |
| Ultimate (7,14,28) | 60.40 | Neutral |
| Momentum (10) | 1.39 | Buy |
| Aroon Osc (25) | 72.00 | Buy |
| Hull MA (9) | 10.90 | Sell |
| ADX (14) | 26.70 | Buy |
| ATR (14) | 0.28 | Info |
The 30-day range is $8.54 to $13.89, and the sentiment is BULLISH. The RSI14 is 70, indicating a momentum tilt near the upper end of the range. The stock trades above the SMA50 of $8.93 and around the SMA200 of $10.66, with resistance at $10.89 and support at $7.50.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $7.47 | $10.85 | $14.40 | 0% | Neutral | |
| $9.56 | $12.32 | $16.96 | +14% | Neutral | |
| $9.61 | $12.86 | $18.52 | +19% | Neutral | |
| $12.06 | $16.65 | $24.84 | +53% | Bullish | |
| $14.34 | $20.34 | $31.26 | +87% | Bullish | |
| $16.24 | $23.62 | $37.25 | +118% | Bullish | |
| $18.14 | $27.01 | $43.58 | +149% | Bullish | |
| $16.30 | $24.82 | $40.87 | +129% | Bullish | |
| $17.41 | $27.07 | $45.44 | +150% | Bullish | |
| $21.68 | $34.41 | $58.78 | +217% | Bullish | |
| $28.73 | $50.10 | $92.07 | +362% | Bullish | |
| $55.11 | $113.76 | $232.22 | +948% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $7.47 | $10.85 | $13.13 | +0.00% |
| August 2026 | $9.49 | $11.29 | $13.84 | +4.03% |
| September 2026 | $9.32 | $11.18 | $13.91 | -0.95% |
| October 2026 | $8.89 | $10.76 | $13.54 | -3.80% |
| November 2026 | $8.95 | $10.89 | $13.85 | +1.30% |
| December 2026 | $9.17 | $11.23 | $14.40 | +3.09% |
Click any year to see its month-by-month ORIC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
ORIC Pharmaceuticals, Inc.'s 2026 outlook centres on $10.85, within a $7.47 to $14.40 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, ORIC could reach as high as $16.96, with a base case around $12.32 and support toward $9.56 — roughly +14% from $10.85. A consolidation phase looks the most probable path here.
Expect ORIC to range from $9.61 to $18.52 through 2028. The $12.86 average target implies a +19% move from current prices. That is up +4% on the projected 2027 average. Price action looks broadly range-bound.
The ORIC price prediction for 2029 points to an average of $16.65 (low $12.06, high $24.84) — a potential gain of +53% on today's $10.85. Buyers look set to stay in control over this stretch.
In 2030, ORIC is projected to trade between $14.34 and $31.26, averaging $20.34 — a potential gain of +87% from today's $10.85. That is up +22% on the projected 2029 average. Momentum favours further upside here.
ORIC Pharmaceuticals, Inc.'s 2031 outlook centres on $23.62, within a $16.24 to $37.25 range. That is up +16% on the projected 2030 average. That marks a +118% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, ORIC could reach as high as $43.58, with a base case around $27.01 and support toward $18.14 — roughly +149% from $10.85. Momentum favours further upside here.
Expect ORIC to range from $16.30 to $40.87 through 2033. The $24.82 average target implies a +129% move from current prices. That is -8% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
The ORIC price prediction for 2034 points to an average of $27.07 (low $17.41, high $45.44) — a potential gain of +150% on today's $10.85. Momentum favours further upside here.
In 2035, ORIC is projected to trade between $21.68 and $58.78, averaging $34.41 — a potential gain of +217% from today's $10.85. That is up +27% on the projected 2034 average. Buyers look set to stay in control over this stretch.
ORIC Pharmaceuticals, Inc.'s 2040 outlook centres on $50.10, within a $28.73 to $92.07 range. That is up +46% on the projected 2035 average. That marks a +362% change versus current levels. Momentum favours further upside here.
By 2050, ORIC could reach as high as $232.22, with a base case around $113.76 and support toward $55.11 — roughly +948% from $10.85. Buyers look set to stay in control over this stretch.
Investing $1,000 in ORIC today (≈ 92.165899 ORIC) could be worth
$10,484.93
+$9,484.93 (+948%) by 2050 · US Dollar
Based on the average projected ORIC price of $113.76 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ORICwould be worth at today's price.
$1,000 invested in ORIC on Jul 10, 2025 (≈ 87.336246 ORIC) would be worth
$947.6
-$52.4 (-5.2%) today · 0.95× · US Dollar
Based on a ORIC entry price of $11.45 vs. today's $10.85.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $11.64 | $932.13 | -6.8% |
| 1 month ago | $7.54 | $1,438.99 | +43.9% |
| 3 months ago | $10.15 | $1,068.97 | +6.9% |
| 6 months ago | $9.15 | $1,185.79 | +18.6% |
| 1 year ago | $11.45 | $947.6 | -5.2% |
| All time (5.0y) ago | $20.46 | $530.3 | -47.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ORIC forecast.
Our base-case forecast reaches $22.00 around 2031.
Implied market cap at $22.00: $2.28B
The multi-year forecast shows a bullish trajectory after a neutral start in 2026. The 2026 forecast lists a min of $7.47, an avg of $10.89, and a max of $14.97 with 0% ROI and neutral sentiment. In 2027, the avg rises to $13.43 with a 23.3% ROI and bullish sentiment, and in 2028 the avg is $15.10 with a 38.7% ROI and bullish sentiment.
The 2029 forecast shows an avg of $20.97 and a 92.6% ROI, with 2030 at an avg of $26.61 and a 144.3% ROI. Further years extend the gains: 2031 avg $31.90 (192.9% ROI), 2032 avg $36.93 (239.1%), 2033 avg $34.49 (216.8%), 2034 avg $40.35 (270.5%), and 2035 avg $54.09 (396.7%). The longer horizon projects stronger upside, with 2040 avg $84.69 (677.7% ROI) and 2050 avg $204.48 (1777.7% ROI), all under bullish sentiment.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $26.61 with a max of $41.50 and a min of $18.50, representing a 144.3% ROI and bullish sentiment.
Forecasts show bullish sentiment in 2027 onward with rising avg prices and positive ROI (e.g., 2027 23.3% ROI, 2029 92.6% ROI, 2050 1777.7% ROI), though 2026 is neutral with 0% ROI.
Yes, the forecast indicates higher price targets in later years, with 2040 avg $84.69 and 2050 avg $204.48; the max for 2040 is $158.99 and the max for 2050 is $427.87, suggesting possible paths above $100 in the extended horizon.
Current price is $10.89 per share and the market cap is $1.13B.
The 30-day range is $8.54 to $13.89. The sentiment is BULLISH, RSI14 is 70, SMA50 is $8.93, SMA200 is $10.66, with support at $7.50 and resistance at $10.89.
ORIC Pharmaceuticals, Inc. Community Discussion
0Share your ORIC Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.